GSTP1 and prostate carcinoma: Recent studies have reported that polymorphisms in GSTP showed a higher risk for the development of resistance to imatinib mesylate for chronic myeloid leukemia patients, and that polymorphisms in GSTM may be responsible for resistance to hormonal therapy in prostate cancer patients37,38.